<p>MiR-140 Resensitizes Cisplatin-Resistant NSCLC Cells to Cisplatin Treatment Through the SIRT1/ROS/JNK Pathway</p>

Zhilai Lin(Fujian Medical University), Yuhua Chen(Fujian Medical University)
OncoTargets and Therapy
August 1, 2020
Cited by 38


Related Papers